Antiviral Properties of a Series of 1,6-Naphthyridine and 7,8-Dihydroisoquinoline Derivatives Exhibiting Potent Activity against Human Cytomegalovirus
- 1 April 2000
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (4) , 929-937
- https://doi.org/10.1128/aac.44.4.929-937.2000
Abstract
A series of 1,6-naphthyridine (L. Chan, H. Jin, T. Stefanac, J. F. Lavallee, G. Falardeau, W. Wang, J. Bedard, S. May, and L. Yuen, J. Med. Chem. 42:3023–3025, 1999) and isoquinoline (L. Chan, H. Jin, T. Stefanac, W. Wang, J. F. Lavallee, J. Bedard, and S. May, Bioorg. Med. Chem. Lett. 9:2583–2586, 1999) analogues exhibiting a high level of anti-human cytomegalovirus (HCMV) activity were investigated in a series of studies aimed at better understanding the mechanism of action of some representatives of this class of compounds. In vitro antiviral profiling revealed that these compounds were active against a narrow spectrum of viruses, essentially the human herpesviruses and type 2 rhinovirus. In HCMV assays, a 39- to 223-fold lower 50% inhibitory concentration was obtained for compound A1 than for ganciclovir against strains AD 169 and Towne. In addition, ganciclovir, foscarnet, cidofovir, and BDCRB (2-bromo-5,6-dichloro-1-β- d -ribofuranosylbenzimidazole)-resistant HCMV strains remained susceptible to 1,6-naphthyridines and 7,8-dihydroisoquinolines tested in this study, supporting the view that a novel mechanism of action could be involved. Drug combination studies showed a small but significant synergistic antiviral effect between compound B2 and ganciclovir. Cytotoxicity profiling of representative compounds under various cell growth conditions indicated a generally similar cytotoxic effect, relative to ganciclovir, in log-phase growing cells. However, in stationary cells, a relatively higher level of toxicity was observed than that for control compound. Effect of time of drug addition showed that the anti-HCMV activity of compound A1, ganciclovir, and cidofovir was lost at approximately the same time (72 h postinfection), indicating that the compound was affecting events at the early and late stage of virus replication. This interpretation is also supported by reduction of de novo synthesis of pp65 tegument protein and lack of any effect of the compound on viral adsorption. A reduction of the HCMV enhancer-promoter-directed luciferase expression was also observed in a stably transfected cell line when compound A1 was present at relatively high concentrations.Keywords
This publication has 41 references indexed in Scilit:
- Discovery of 1,6-Naphthyridines as a Novel Class of Potent and Selective Human Cytomegalovirus InhibitorsJournal of Medicinal Chemistry, 1999
- Design, Synthesis, and Antiviral Evaluation of 2-Substituted 4,5-Dichloro- and 4,6-Dichloro-1-β-d-ribofuranosylbenzimidazoles as Potential Agents for Human Cytomegalovirus InfectionsJournal of Medicinal Chemistry, 1997
- Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patientsJournal of Medical Virology, 1995
- Suppression of Activation of the Human Immunodeficiency Virus Long Terminal Repeat by CD8+T Cells Is Not Lentivirus SpecificAIDS Research and Human Retroviruses, 1995
- Frequency of UL97 Phosphotransferase Mutations Related to Ganciclovir Resistance in Clinical Cytomegalovirus IsolatesThe Journal of Infectious Diseases, 1995
- Analysis Of The Ul97 Phosphotransferase Coding Sequence In Clinical Cytomegalovirus Isolates And Identification Of Mutations Conferring Ganciclovir ResistanceThe Journal of Infectious Diseases, 1995
- Selective inhibition of cytomegaloviruses by 9-(3′-ethylphosphono-1′-hydroxymethyl-1′-propyloxy-methyl)guanineAntiviral Research, 1993
- Activity of different antiviral drug combinations against human cytomegalovirus replication in vitroEuropean Journal of Clinical Microbiology & Infectious Diseases, 1992
- A three-dimensional model to analyze drug-drug interactionsAntiviral Research, 1990
- Death in the AIDS Patient: Role of CytomegalovirusNew England Journal of Medicine, 1983